Smartlab Europe

Clinical Trials

Algernon completes patient enrollment in phase 2b/3 study of Ifenprodil to treat COVID-19

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that the final patient has been enrolled in its multinational phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The aggregate total number of patients enrolled from...

Bharat Biotech underplays adverse event in Covaxin Phase 1 trial as start date for Phase 3 nears

Bharat Biotech, during its phase 1 trials, experienced an adverse event in a volunteer that it did not promptly admit to the public. As per a statement from the vaccine maker, the event was reported in a timely manner...

Astrazeneca Says AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were...

EUA Begins Rolling Review of Modernas mRNA Vaccine Candidate Against COVID-19

Moderna, Inc.,a biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that the EMA human medicines committee (CHMP) has started a rolling review of mRNA-1273, the Company’s vaccine candidate...

Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients

Mallinckrodt plc, a global biopharmaceutical company, announced initiation of a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE)" to collect real-world data on the use of INOmax® (nitric oxide) gas, for inhalation therapy in patients...

Cancer Treatment Can Be Cloned For COVID-19

As per the recent international study by the scientists from Italy & Australia, Beta-blockers have it in them to be a potential treatment for COVID-19. The scientists are now calling for Clinical Trials to support the research findings. Dr. Nirmal...

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Pfizer Inc. and BioNTech SE announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »